Relay Therapeutics, Inc. (RLAY) annual cash flow statement — 8-year operating, investing & financing history
| Cash from Operations | -213.36M | -235.46M | -249.11M | -300.32M | -229.49M | -74.41M | -102.49M | -66.13M | -44.13M |
| Operating CF Margin % | - | -1533.41% | -2489.33% | -1175.59% | -16617.67% | -2456.45% | -124% | - | - |
| Operating CF Growth % | 85.98% | 5.48% | 17.05% | -30.86% | -208.43% | 27.4% | -54.97% | -49.84% | - |
| Net Income | -272.7M | -276.48M | -337.71M | -341.97M | -290.51M | -363.87M | -52.41M | -75.31M | -48.78M |
| Depreciation & Amortization | -180K | -1.39M | 5.46M | 5.27M | 4.13M | 3.92M | 3.55M | 2.85M | 2.15M |
| Stock-Based Compensation | 53.63M | 62.42M | 94.14M | 86.03M | 56.14M | 48.45M | 31.96M | 4.46M | 2.89M |
| Deferred Taxes | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Non-Cash Items | 14.12M | 3.3M | -25.62M | -17.18M | -10.49M | 139.74M | -416K | -2.44M | 9K |
| Working Capital Changes | -8.22M | -23.31M | 14.62M | -32.46M | 11.25M | 97.34M | -85.17M | 4.31M | -400K |
| Change in Receivables | 0 | 0 | 0 | 5.22M | 97K | 77.79M | -75M | 0 | 0 |
| Change in Inventory | 0 | 0 | 0 | 0 | 0 | 0 | -10.33M | 0 | 0 |
| Change in Payables | -4.33M | -11.44M | 0 | -2.39M | 1.99M | 930K | -410K | 3M | 1.23M |
| Cash from Investing | 183.24M | 192.8M | -41.08M | 257.63M | -188.75M | -479.51M | 81.67M | -319.02M | -1.68M |
| Capital Expenditures | -26K | -410K | -2.02M | -4.13M | -9.06M | -3.47M | -1.93M | -8M | -1.69M |
| CapEx % of Revenue | 0.24% | 2.67% | 20.17% | 16.15% | 656.19% | 114.59% | 2.34% | - | - |
| Acquisitions | 0 | 0 | 0 | 0 | 179.68M | -25.3M | -83.6M | 0 | 7K |
| Investments | - | - | - | - | - | - | - | - | - |
| Other Investing | 0 | 0 | 0 | 0 | -179.68M | 0 | 83.6M | 20K | 7K |
| Cash from Financing | 140.39M | 1.6M | 270.15M | 34.75M | 289.91M | 388.09M | 426.51M | 5.61M | 394.97M |
| Debt Issued (Net) | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Equity Issued (Net) | 1.6M | 1.6M | 265.89M | 30.28M | 284.74M | 382.21M | 425.29M | 4.99M | 394.25M |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Share Repurchases | 653K | 0 | 0 | 0 | 0 | 0 | 0 | 0 | -82K |
| Other Financing | 138.78M | 0 | 4.26M | 4.47M | 5.17M | 5.88M | 1.22M | 613K | 717K |
| Net Change in Cash | 110.26M | -41.05M | -20.04M | -7.93M | -128.32M | -165.83M | 405.69M | -379.55M | 349.16M |
| Free Cash Flow | -213.38M | -235.87M | -251.13M | -304.44M | -238.55M | -77.88M | -104.42M | -74.14M | -45.82M |
| FCF Margin % | -1998.53% | -1536.08% | -2509.49% | -1191.74% | -17273.86% | -2571.05% | -126.33% | - | - |
| FCF Growth % | 21.73% | 6.08% | 17.51% | -27.62% | -206.32% | 25.42% | -40.85% | -61.79% | - |
| FCF per Share | -1.19 | -1.37 | -1.76 | -2.48 | -2.13 | -0.82 | -1.16 | -17.32 | -18.44 |
| FCF Conversion (FCF/Net Income) | 0.78x | 0.85x | 0.74x | 0.88x | 0.79x | 0.20x | 1.96x | 0.99x | 0.90x |
| Interest Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Taxes Paid | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Quick answers to the most common questions about buying RLAY stock.
Relay Therapeutics, Inc. (RLAY) generated $-235.5M in net cash from operating activities in 2025. This reflects the cash generated directly from core business operations.
Relay Therapeutics, Inc. (RLAY) reported negative free cash flow of $235.9M in 2025, indicating capital requirements exceeded cash from operations.
Relay Therapeutics, Inc. (RLAY) spent $0.4M on capital expenditures in 2025. CapEx represents the cash invested in physical assets like property, plant, and equipment to maintain or grow the business.